Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Patent
1995-06-07
1998-11-03
Housel, James C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
4241361, 4241431, 4241501, 4241781, 4242361, 4242381, 5303873, 5303917, A61K 39395
Patent
active
058304789
ABSTRACT:
The method of the present invention employs a hybrid reagent comprising a first portion (i.e., a cell-targeting portion) which binds to cell surfaces coupled to a second portion (i.e., a toxin-binding portion) which binds to, or has bound to it, an endosomally active domain of DT and releases the endosomally active domain of DT in response to the low pH in endosomal vesicles of cells. Thus, the second portion of the hybrid reagent binds an endosomally active domain directly (e.g., an antibody which binds to all or a portion of the T domain of DT) or indirectly (e.g., an antibody which binds to the R domain of a moiety in which the R domain of DT is coupled to the T domain of DT). A second endosomally active domain of DT, which is different from the first endosomally active domain of DT, is delivered to the same endosomal vesicles separately. The independent endosomally active domains of DT are not toxic to cells until they meet within the endosomes. Thus, the therapeutic window of the binary toxin described herein is much greater than current toxin delivery systems, which generally retain collateral toxicity, even when undelivered.
REFERENCES:
patent: 4664911 (1987-05-01), Uhr et al.
patent: 5603931 (1997-02-01), Raso
Raso, V., "Immunotargeting Intracellular Compartments", Anal. Biochem., 222:297-304 (1994).
Greenfield, L. et al., "Mutations in Diphtheria Toxin Separate Binding from Entry and Amplify Immunotoxin Selectivity", Science, 238:536-538 (1987).
Neville, D.M., Jr. et al., "Enhancement of Immunotoxin Efficacy by Acid-Cleavable Cross-Linking Agents Utilizing Diphtheria Toxin and Toxin Mutants", J. Biol. Chem., 264 (25) :14653-14661 (1989).
Raso, V., "Antibody Mediated Delivery of Cytotoxic Molecules to Antigen Bearing Target Cells", Immunol. Rev., 62:93-117 (1982).
Paik, C.H. et al., "Reduction of Background Activities by Introduction of a Diester Linkage Between Antibody and Chelate in Radioimmunodetection of Tumor", J. of Nuclear Medicine, 30 (10) :1693-1701 (1989).
Myers, D.A. et al., Specific Chemicl Cleavage of Diphtheria Toxin with Hydroxylamine, J. Biol. Chem., 263 (32) :17122-17127 (1988).
Murphy, J.R. et al., "Genetic Construction, Expression and Melanoma-Selective Cytotoxicity of Diphtheria Toxin-Related .alpha.-Melanocyte-Stimulating Hormone Fusion Protein", Proc. Natl. Acad. Sci., USA, 83:8258-8262 (1986).
Bacha, P. et al., "Interleukin 2 Receptor-Targeted Cytotoxicity", J. Exp. Med., 167:612-622 (1988).
Raso, V et al., "Hybrid Antibodies with Dual Specificity for the Delivery of Immunoglobulin-bearing Target Cells", Cancer Research, 41:2073-2078 (1981).
Vitetta, E.S., et al., "Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of nepolastic human B cells," Proc. Natl. Acad. Sci. USA 80:6332-6335.
Raso Victor A.
Sheldon Katherine
Boston Biomedical Research Institute
Housel James C.
Shaver Jennifer
LandOfFree
Method for delivering functional domains of diphtheria toxin to does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for delivering functional domains of diphtheria toxin to , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for delivering functional domains of diphtheria toxin to will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-686747